Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company, announced it will report its Q1 2026 financial results and provide a business update after U.S. market close on May 7, 2026. The company is advancing clinical trials for its lead drug azetukalner and other ion channel modulators targeting epilepsy, depression, and pain.